EDAP TMS Reports Record Focal One® Sales and Growth in Prostate Cancer Procedures

EDAP TMS ( (EDAP) ) has provided an update.

EDAP TMS announced preliminary record sales for the fourth quarter of 2024 for their Focal One® system, a robotic HIFU technology used in treating prostate cancer. The company reported robust demand, particularly in the U.S., with a 30% year-over-year increase in procedures, indicating growing adoption and transformative impact in urological practices. This performance is expected to further drive awareness and adoption, supported by recent scientific publications.

More about EDAP TMS

EDAP TMS is a recognized leader in robotic energy-based therapies, developing, manufacturing, and distributing minimally invasive medical devices worldwide. The company specializes in ultrasound technology, offering the Focal One® system, a leading prostate focal therapy controlled by urologists, with potential applications beyond prostate cancer.

YTD Price Performance: -12.50%

Average Trading Volume: 168,190

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $77.92M

See more insights into EDAP stock on TipRanks’ Stock Analysis page.